The recently licensed subunit hepatitis B vaccine (HEPTAVAX-B) is unique among vaccines in that it is manufactured solely from human plasma obtained from asymptomatic individuals with chronic hepatitis B. Plasma from donors selected for manufacturing this vaccine contains high concentrations of noninfectious hepatitis B surface antigen (HBsAg) particles and lower concentrations of infectious hepatitis B virus (HBV). The ratio of HBsAg to HBV can be as great as 10,000:1 (1). From the starting plasma, 22 nm spherical HBsAg particles are separated from HBV by ultracentrifugation. The 22 nm particles are then further purified by digestion with pepsin followed by the addition of 8M urea. Finally, the vaccine is treated with formaldehyde.
KeywordsNewcastle Disease Virus Acquire Immune Deficiency Syndrome Infectious Bronchitis Virus Homosexual Male Hemophilic Patient
Unable to display preview. Download preview PDF.
- 2.Code of Federal Regulations, part 21, section 640. Government Printing Office, 1979.Google Scholar
- 3.FDA Guidelines: Clarification of Guidelines for Plasmapheresis of HBsAg Reactive Donors. Bethesda, MD, Food and Drug Administration, March 1981.Google Scholar
- 4.Hilleman, M. R., Buynak, E. B., McAleer, W. M., et al. (1982). Hepatitis A and hepatitis B vaccines, in Viral Hepatitis, 1981 International Symposium, W. Szmuness, H. J. Alter and J. E. Maynard, eds., Franklin Institute Press, Philadelphia, pp. 385–397.Google Scholar
- 5.Tabor, E., Buynak, E., Smallwood, L. A., et al. Inactivation of hepatitis B virus by three methods: Treatment with pepsin, urea, or formalin. J. Med. Virol., in press.Google Scholar
- 13.Hepatitis B virus vaccine safety: Report on an inter-agency group. (1982). MMWR 31:465–467.Google Scholar
- 14.Centers for Disease Control Special Report: Epidemiologic aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infection. (1982). N. Engl. J. Med. 306:248–252.Google Scholar
- 20.Pneumocystis carinii pneumonia among persons with hemophilia A. (1982). MMWR 31:365–367.Google Scholar
- 21.Tabor, E. (1982). Infectious Complications of Blood Transfusion, Academic Press Inc., New York.Google Scholar
- 23.Inactivated hepatitis B virus vaccine. (1982). MMWR 31: 318–328.Google Scholar